ArriVent

Nasdaq: AVBP · SEC EDGAR filings

Results on file1
Average 24h move−48.74%across 1 result with a complete 24h price
1 resultArriVent
Missed endpoint

Firmonertinib

Phase 3 n=398 Metastatic Non-Small Cell Lung Cancer

ArriVent AVBP

24h stock move −48.74%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.